The Priority Review

Clinical trials Brief

Sanofi registers Phase 3 study of dupilumab coformulation in atopic dermatitis

The study, led by Sanofi and collaborating with Regeneron Pharmaceuticals, plans to enroll 150 participants and begin on November 30, 2026. It compares the pharmacokinetics, immunogenicity and safety of dupilumab coformulated with berahyaluronidase alfa to the approved dupilumab formulation in adults and adolescents with moderate-to-severe atopic dermatitis.

Primary source

ClinicalTrials.gov registry record, November 5, 2026

Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation

Read the source: Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation